foxo4 dri senolytic 2023 2024 foxo4-dri peptide human trial FOXO4-DRI UK The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Senolytic Drugs Market to Reach USD 667.6 Million by 2033 Senolytics: charting a new course or enhancing existing anti tumor therapies? Cellular Oncology Springer Nature Link FOXO4 DRI improves spermatogenesis in aged mice through reducing senescence associated secretory phenotype secretion from Leydig cells ScienceDirect
Pay in 4 interest-free payments of $5.46 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 17 - Sep 22



